11 results about "Maple syrup" patented technology

The present disclosure relates to a sugar substitute composition comprising components selected from at least one regular sugar, maple syrup, and honey, at least one herb extract, at least one soluble fiber, at least one natural sweetener, at least one sugar alcohol, at least one anti-caking agent, and at least one vitamin and minerals. The composition substantially reduces the ill-effects of consuming regular sugar.

The present disclosure provides alcoholic drinks using maple syrup as a raw material and methods for the preparation. The maple syrup, with its sugar concentration of 66% and its pristine and pure properties, stimulates an easy initiation of a fermentation, and the methods do not yield any waste or impurities after fermentation, which is more environmentally friendly. Additionally, the present disclosure employs a maple wood barrel storing and aging the alcoholic drink, augmenting the aroma and quality of the maple syrup wine further.

An edible organic baby teether is disclosed, comprising a frozen therapeutic confectionery formulated from organic nut butter and natural sweeteners, shaped to be safely chewed and consumed by infants for relief of teething discomfort. The invention provides a dual-function teething aid that offers both cooling therapy and nutritional benefit, eliminating the risks associated with synthetic or non-edible teethers. In the preferred embodiment, the composition includes almond, peanut, or cashew butter blended with organic honey, agave nectar, or maple syrup, molded into a popsicle form with an integrated edible or biodegradable handle for infant grasping. When frozen, the product delivers a soothing, gum-numbing effect, and as it softens, it may be safely ingested, providing essential nutrients such as proteins and healthy fats. A method of manufacture is also disclosed, including steps of mixing, molding, freezing, and packaging the organic composition to achieve a soft-freeze texture optimized for infant safety and enjoyment.

The present invention features palatable pharmaceutical compositions including sodium phenylbutyrate and methods for the treatment of inborn errors of metabolism (e.g., Maple Syrup Urine Disease or Urea Cycle Disorders), neurodegenerative disorders such as Parkinson's disease, spinal muscular atrophy, dystonia, or inclusion-body myositis with such compositions.

This disclosure relates to mRNA therapy for the treatment of maple syrup urine disease (MSUD). mRNAs for use in the invention, when administered in vivo, encode branched chain α-ketoacid dehydrogenase complex (BCKDC) E1α, E1β, or E2mRNA therapies of the disclosure increase and / or restore deficient levels of E1α, E1β, or E2 expression and / or BCKDC activity in subjects. mRNA therapies of the invention further decrease abnormal accumulation of branched chain amino acids associated with deficient BCKDC activity in subjects.

1. The name of the design product: wine bottle (maple tree cellar). 2. The use of the design product: as a package for wine. 3. The design points of the design product: the shape, pattern and combination of the product of the patent design. 4. The picture or photo that best indicates the design points: perspective view.

To provide a pharmaceutical product that has B0AT1 inhibitory activity. [Solution] The present invention is based on formula (I): [C1] TIFF2026066243000332.tif44170 [In the formula, each symbol is as described in the specification.] The present invention relates to a pharmaceutical composition containing a compound represented by or a salt thereof, and a B0AT1 inhibitor. One embodiment of the present invention is a pharmaceutical suitable for the prevention and / or treatment of amino acid metabolic disorders such as phenylketonuria, urea cycle disorders, hypertyrosinemia (types 1-3), hypermethioninemia, maple syrup urine disease, homocystinuria, nonketotic hyperglycinemia, propionic acidemia, methylmalonic acidemia, and isovaleric acidemia.

To provide a palatable sodium phenylbutyrate formulation for improving patient compliance, methods of making the same, and methods of treatment.SOLUTION: Palatable compositions comprising sodium phenylbutyrate and a taste-mask coating, and methods of treating congenital metabolic disorder (e.g., Maple syrup urine disease or urea cycle disorders), neurodegenerative disorders such as Parkinson's, spinal muscular atrophy, dystonia, or inclusion body myositis using such compositions are provided.SELECTED DRAWING: None

A system for non-invasive microwave testing a bottle of liquid may include an emission probe for emitting a microwave signal through a wall of the bottle into the liquid and a detection probe for receiving at least a portion of the microwave signal from the liquid via the wall. The system includes a classifier configured to distinguish olive oil from some other common vegetable oils, to distinguish real from some imitation maple syrups, and to distinguish between several alcoholic beverages.

In some aspects the disclosure provides compositions and methods for promoting expression of functional BCKDHA protein, which is the E1-alpha subunit of the branched-chain alpha-keto acid (BCAA) dehydrogenase complex, in a subject. In some aspects the disclosure provides compositions and methods for promoting expression of functional BCKDHB protein, which is the E1-beta subunit of the branched-chain alpha-keto acid (BCAA) dehydrogenase complex, in a subject. In some aspects the disclosure provides compositions and methods for promoting expression of functional BCKDHA and BCKDHB proteins, in a subject. In some embodiments, the disclosure provides methods of treating a subject having Maple Syrup Urine Disease (MSUD).

The present invention relates to a compound having a BOAT1 inhibitory action and represented by the following formula (I):wherein each symbol is as defined in the specification, or a salt thereof. In addition, the present invention relates to a BOAT1 inhibitor containing the aforementioned compound and a pharmaceutical composition containing the aforementioned compound. One embodiment of the present invention is, for example, a medicament preferable for the prophylaxis and / or treatment of amino acid metabolism disorders such as phenylketonuria, urea cycle disorder, hypertyrosinemia (types 1-3), hypermethioninemia, maple syrup urine disease, homocystinuria, nonketotic hyperglycinemia, propionic acidemia, methylmalonic acidemia, isovaleric acidemia and the like.